Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
GU Cancer ASCO 2024 Highlights
Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.
Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.
Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.
Toni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
